Edward G D Tuddenham
Overview
Explore the profile of Edward G D Tuddenham including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
39
Citations
2978
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tuddenham E, Foster G
J Viral Hepat
. 2024 Apr;
31 Suppl 1:21-25.
PMID: 38606938
Attempts to achieve a functional cure or amelioration of the severe X linked bleeding disorders haemophilia A (factor VIII deficiency) and haemophilia B (factor IX deficiency) using AAV-based vectors have...
2.
Owen M, Wright J, Tuddenham E, King J, Goodall A, Dunster J
J Thromb Haemost
. 2024 Mar;
22(6):1689-1703.
PMID: 38521192
Background: Mathematical models of coagulation have been developed to mirror thrombin generation in plasma, with the aim of investigating how variation in coagulation factor levels regulates hemostasis. However, current models...
3.
Nathwani A, Tuddenham E
Br J Haematol
. 2020 Nov;
191(4):573-578.
PMID: 33190257
The single most important step on the path to our modern understanding of blood coagulation and haemophilia in the 20th century was taken by British pathologist Robert Gwyn Macfarlane with...
4.
Ling G, Tuddenham E
Br J Haematol
. 2020 Jan;
189(3):400-407.
PMID: 31900934
The foundation of haemophilia A therapy in the last 35 years has been critically dependent on isolation of the Factor VIII (FVIII) protein and discovery of the cDNA sequence of...
5.
Interaction Between the a3 Region of Factor VIII and the TIL'E' Domains of the von Willebrand Factor
Dagil L, Troelsen K, Bolt G, Thim L, Wu B, Zhao X, et al.
Biophys J
. 2019 Jul;
117(3):479-489.
PMID: 31349985
The von Willebrand factor (VWF) and coagulation factor VIII (FVIII) are intricately involved in hemostasis. A tight, noncovalent complex between VWF and FVIII prolongs the half-life of FVIII in plasma,...
6.
Ling G, Nathwani A, Tuddenham E
Br J Haematol
. 2018 Jan;
181(2):161-172.
PMID: 29359795
Haemophilia therapy has undergone very rapid evolution in the last 10 years. The major limitation of current replacement therapy is the short half-life of factors VIII and IX. These half-lives...
7.
Nathwani A, Davidoff A, Tuddenham E
Hematol Oncol Clin North Am
. 2017 Sep;
31(5):853-868.
PMID: 28895852
The best currently available treatments for hemophilia A and B (factor VIII or factor IX deficiency, respectively) require frequent intravenous infusion of highly expensive proteins that have short half-lives. Factor...
8.
Nathwani A, Davidoff A, Tuddenham E
Hum Gene Ther
. 2017 Aug;
28(11):1004-1012.
PMID: 28835123
Gene therapy provides hope for a cure for patients with hemophilia by establishing continuous endogenous expression of factor VIII or factor IX following transfer of a functional gene copy to...
9.
Nathwani A, Reiss U, Tuddenham E, Rosales C, Chowdary P, McIntosh J, et al.
N Engl J Med
. 2014 Nov;
371(21):1994-2004.
PMID: 25409372
Background: In patients with severe hemophilia B, gene therapy that is mediated by a novel self-complementary adeno-associated virus serotype 8 (AAV8) vector has been shown to raise factor IX levels...
10.
Shiltagh N, Kirkpatrick J, Cabrita L, McKinnon T, Thalassinos K, Tuddenham E, et al.
Blood
. 2014 Apr;
123(26):4143-51.
PMID: 24700780
Although much of the function of von Willebrand factor (VWF) has been revealed, detailed insight into the molecular structure that enables VWF to orchestrate hemostatic processes, in particular factor VIII...